Theriva Biologics Statistics
Total Valuation
TOVX has a market cap or net worth of $3.76 million. The enterprise value is -$3.31 million.
Important Dates
The last earnings date was Wednesday, May 14, 2025, before market open.
Earnings Date | May 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
TOVX has 8.19 million shares outstanding. The number of shares has increased by 181.75% in one year.
Current Share Class | 8.19M |
Shares Outstanding | 8.19M |
Shares Change (YoY) | +181.75% |
Shares Change (QoQ) | -0.37% |
Owned by Insiders (%) | 0.16% |
Owned by Institutions (%) | 6.96% |
Float | 8.17M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.08 |
P/TBV Ratio | 0.25 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.18.
Current Ratio | 1.53 |
Quick Ratio | 1.44 |
Debt / Equity | 0.18 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -100.01% and return on invested capital (ROIC) is -41.14%.
Return on Equity (ROE) | -100.01% |
Return on Assets (ROA) | -27.71% |
Return on Invested Capital (ROIC) | -41.14% |
Return on Capital Employed (ROCE) | -74.68% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.13M |
Employee Count | 22 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.58% in the last 52 weeks. The beta is 0.83, so TOVX's price volatility has been lower than the market average.
Beta (5Y) | 0.83 |
52-Week Price Change | -92.58% |
50-Day Moving Average | 0.95 |
200-Day Moving Average | 1.63 |
Relative Strength Index (RSI) | 30.37 |
Average Volume (20 Days) | 1,873,176 |
Short Selling Information
The latest short interest is 172,674, so 2.11% of the outstanding shares have been sold short.
Short Interest | 172,674 |
Short Previous Month | 96,649 |
Short % of Shares Out | 2.11% |
Short % of Float | 2.11% |
Short Ratio (days to cover) | 0.07 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -17.93M |
Pretax Income | -20.35M |
Net Income | -24.81M |
EBITDA | -17.81M |
EBIT | -17.93M |
Earnings Per Share (EPS) | -$13.25 |
Full Income Statement Balance Sheet
The company has $10.01 million in cash and $2.86 million in debt, giving a net cash position of $7.16 million or $0.87 per share.
Cash & Cash Equivalents | 10.01M |
Total Debt | 2.86M |
Net Cash | 7.16M |
Net Cash Per Share | $0.87 |
Equity (Book Value) | 15.50M |
Book Value Per Share | 5.57 |
Working Capital | 4.33M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$16.81 million and capital expenditures -$1,000, giving a free cash flow of -$16.81 million.
Operating Cash Flow | -16.81M |
Capital Expenditures | -1,000 |
Free Cash Flow | -16.81M |
FCF Per Share | -$2.05 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |